Analysis of samples with 100 protein panel.

The contract involves a study aimed at identifying patterns of metabolites, both endogenous and exogenous, that correlate with a set of proteins proposed as predictors of cardiovascular disease (CVD) risk. The focus is on analyzing samples using a panel consisting of 100 proteins to better understand the relationship between these metabolites and CVD risk indicators. The project is categorized under the NAICS code 541990 and is issued by the Food and Drug Administration. This opportunity is a forecast type contract with no specific solicitation number provided and lacks detailed information about the place of performance or specific organization type. The primary contact point for this contract is the FDA's acquisition liaison, with the contracting officer yet to be determined. The study aims to enhance predictive capabilities for cardiovascular disease by leveraging biochemical markers, reflecting the FDA's interest in advancing diagnostics and risk assessment tools in cardiovascular health.